Understanding and Managing the Burden of Pediatric and Adolescent ADHD: Practical Strategies for Diagnosing and Treating ADHD and Comorbidities Across the Continuum of Care CME

Mark L. Wolraich, MD; Betsy Busch, MD,FAAP; James T. McCracken, MD Author Information and Disclosures

Release Date: July 1, 2008; Valid for credit through July 1, 2009

Credits Available
Physicians - maximum of 1.75 AMA PRA Category 1 Credit(s)™ for physicians

This CME-certified activity is based on a live symposium that was held in Honolulu, Hawaii, on May 5, 2008.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 University of Kentucky.
McNeil Pediatrics
Learning Objectives

Upon completion of this activity, participants should be able to:

  1. Discuss the prevalence of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents and its potential effects if left untreated
  2. Recognize and manage (or refer) patients with psychiatric comorbidities associated with ADHD
  3. Describe the safety and efficacy of all available treatment options, including pharmacologic and nonpharmacologic strategies
  4. Tailor treatment selection to the individual patient, based on ADHD subtype, comorbidities, and other relevant patient factors
  5. Assess symptom and behavior outcomes following initiation of treatment of the child or adolescent with ADHD
Authors and Disclosures

Mark L. Wolraich, MD
Disclosure: Contract Research Support: Eli Lilly and Company, Shire Consultation Fee: Abbott Laboratories, Eli Lilly and Company.


Betsy Busch, MD,FAAP
Disclosure: Speakers' Bureau: McNeil Pediatrics, Shire; Consultation Fees: Cephalon Inc., Eli Lilly and Company, Forest Laboratories, Inc., McNeil Pediatrics.


James T. McCracken, MD
Disclosure: Contract Research Support: Aspect Pharmaceuticals, Bristol-Myers Squibb Company, Eli Lilly and Company; Consultation Fees: Pfizer Inc, sanofi-aventis, Wyeth.


Allen J. Brenzel, MD, MBA, FAAP
Disclosure: Division of Child and Adolescent Psychiatry, Department of Psychiatry, College of Medicine University of Kentucky, Lexington, Kentucky.
 
University of Kentucky
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of the University of Kentucky College of Medicine. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentation is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.